SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as traders speculate on the timing of topline data from the Phase 3 REGAL trial, with community discussion intensely divided between those anticipating a positive outcome for the leukemia treatment and those warning of potential clinical failure or dilution risks. While long-term investors highlight the extended trial duration as a positive signal of drug efficacy, bearish voices point to the lack of official updates and ongoing legal investigations as reasons for caution.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble shares are trending as traders react to a report identifying Anthropic as the unnamed customer behind the company's previously announced $13.7 billion compute infrastructure deal. While some investors see this as a major growth catalyst, others express frustration over the timing and the potential for dilution, leading to mixed sentiment and significant volatility.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing downward pressure amid renewed volatility in the semiconductor sector and broader market concerns regarding high interest rates, inflation, and tensions in the Middle East. Traders are actively debating the sustainability of the AI trade, with many expressing frustration over the ETF's daily choppiness and aggressive price swings.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Investors are expressing frustration with recent price action, often citing heavy capital expenditure on AI infrastructure as a drag on sentiment despite strong cloud growth, while some traders discuss speculative rumors regarding potential breakthroughs or regulatory risks. The community remains divided, with many long-term bulls advocating for holding through volatility, while others speculate on further downside potential based on macro-uncertainty and historical September trends.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as traders speculate on a potential re-rating from a legacy telecom provider into a key AI infrastructure and networking player, bolstered by new partnerships, its upcoming inclusion in the Euro STOXX 50 index, and its involvement in AI-focused projects. While sentiment is divided between long-term bullish investors anticipating further expansion and skeptics who highlight the stock's massive share float and persistent price stagnation, many are focused on the expected institutional buying triggered by the index rebalancing.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending following the release of positive topline results from the Phase 3 Voyage study, which met its primary and secondary endpoints in treating generalized anxiety disorder. Investors are now awaiting additional Phase 3 data for the company's LSD-based drug, DT120, later in the quarter, as market attention remains focused on its potential for regulatory submission.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is experiencing significant price volatility as the community debates the long-term sustainability of the AI infrastructure boom, with traders weighing massive compute backlog and partnerships against concerns over high debt levels and aggressive insider selling. Discussion is further intensified by conflicting market sentiment regarding the future of AI development and the impact of broader macroeconomic factors like rising bond yields.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending following Executive Chair Larry Ellison's unexpected cancellation of a plan to sell 50 million shares, a move retail traders view as a bullish signal that could trigger a short squeeze. While sentiment is driven by this development, investors remain divided on the long-term impact of rising restructuring costs, aggressive AI infrastructure spending, and industry-wide debate over the pace of AI development.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Investors are expressing concern over a potential slowdown in AI infrastructure development following a coordinated push by industry leaders to prioritize safety, while also weighing the impact of rising oil prices and Treasury yields ahead of the upcoming Federal Reserve policy meeting. This has led to a shift toward bearish sentiment among traders as they grapple with inflationary pressures and ongoing volatility in the tech sector.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as retail traders debate the impact of industry leaders' calls for a slowdown in frontier AI development on future capital expenditure. While some investors fear a potential shift in the AI infrastructure buildout cycle, others argue that long-term demand for memory and compute remains intact.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stifel reiterated $TNGX Buy-$40 and said -- Expectations for the vopimetostat+RAS(ON) inhibitor combination ESMO 2026 poster? Expect longer follow-up from the June disclosure, with some additional patients. 
$RVMD $IMRX ERAS BBOT 
Stifel added—Management cautioned against expecting too many newly enrolled patients to be reflected in ESMO efficacy data – time window is pretty narrow to enroll patients who would have the 14+ weeks of required follow-up to be efficacy evaluable by the ESMO data cut-off. 
 
Investors expect around a doubling of the efficacy evaluable vopi+darax patients in PDAC (DL1+DL2) in the ESMO poster. 
 
This plays well for the 92% ORR holding up reasonably well, newly evaluable patients would have to meaningfully underperform the original n = 12 to pull down the ORR. 
 
Management said enrolling more patients in the vopi+darax dose level 1 has been their priority.

Obvs Not Telling

Guggenheim⬆️ $TNGX to $35, keeps Buy/said: 
TNGX reported 2Q26 results and highlighted that they will finalize the design of a planned Phase 3 randomized controlled trial for vopimetostat (PRMT5i) + RAS inhibitors ( $RVMD) in 1L PDAC in 2H26. 
IMRX $ERAS BBOT 
Here&#39;s what else Guggenheim had to say: https://x.com/Quantumup1/status/2087528805401280908?s=20

Guggenheim⬆️ $TNGX to $35, keeps Buy/said:TNGX reported 2Q26 results and highlighted that they will finalize the design of a planned Phase 3 randomized controlled trial for vopimetostat (PRMT5i) + RAS inhibitors ( $RVMD) in 1L PDAC in 2H26.IMRX $ERAS BBOTGuggenheim added-Our... https://t.co/MDTqqDWazH

quantumup on X (formerly Twitter): "Guggenheim⬆️ $TNGX to $35, keeps Buy/said:TNGX reported 2Q26 results and highlighted that they will finalize the design of a planned Phase 3 randomized controlled trial for vopimetostat (PRMT5i) + RAS inhibitors ( $R...

StockTwits Web

Tango Therapeutics Inc

Revolution Medicines Inc

Erasca Inc

Quantumup

Immuneering Corp

 Buy-$40 and said -- Expectations for the vopimetostat+RAS(ON) inhibitor combination ESMO 2026 poster? Expect longer follow-up from the June disclosure, with some additional patients. 


 ERAS BBOT 
Stifel added—Management cautioned against expecting too many newly enrolled patients to be reflected in ESMO efficacy data – time window is pretty narrow to enroll patients who would have the 14+ weeks of required follow-up to be efficacy evaluable by the ESMO data cut-off. 
 
Investors expect around a doubling of the efficacy evaluable vopi+darax patients in PDAC (DL1+DL2) in the ESMO poster. 
 
This plays well for the 92% ORR holding up reasonably well, newly evaluable patients would have to meaningfully underperform the original n = 12 to pull down the ORR. 
 
Management said enrolling more patients in the vopi+darax dose level 1 has been their priority.